FDA approves taletrectinib for ROS1-positive non-small cell ...
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...
Description: The purpose of this document is to discuss the clinical considerations and general management of taletrectinib for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). …
ROS1+ NSCLC Treatment | IBTROZI™ (taletrectinib)
PLAY ON IBTROZI is a nonchemotherapy, targeted oral treatment designed specifically for adults with ROS1+ NSCLC What is IBTROZI? IBTROZI™ (taletrectinib) is a prescription medicine used to treat …
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Jun 13, 2025 · FDA approval of Taletrectinib for ROS1 positive Non Small Cell Lung Cancer Taletrectinib was approved by the U.S. Food and Drug Administration (FDA) on June 11, 2025, for …
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC
Jun 25, 2025 · The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers (NSCLC) have added taletrectinib (Ibtrozi) as a preferred …
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST
Apr 3, 2025 · Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies …
FDA Approves Taletrectinib in ROS1+ NSCLC - CancerNetwork
Jun 11, 2025 · The FDA has approved taletrectinib (Ibtrozi) for patients with locally advanced or metastatic ROS1 -positive non–small cell lung cancer (NSCLC), according to a press release from …
IBTROZI for the Treatment of Non-small Cell Lung Cancer, US
Dec 9, 2025 · IBTROZI™ (taletrectinib) is a non-chemotherapy, targeted oral medicine available as 200mg capsules. Credit: Nuvation Bio, Inc. IBTROZI ™ (taletrectinib) is a tyrosine kinase inhibitor …
Ibtrozi™ (Taletrectinib) | A New Era in ROS1-Positive NSCLC ...
Jun 22, 2025 · Ibtrozi™ (taletrectinib) is a next-generation, oral ROS1 tyrosine kinase inhibitor (TKI), approved by the U.S. FDA on June 11, 2025. It’s designed to treat adult patients with locally …
Taletrectinib Approved for ROS1-Positive NSCLC | AJMC
Jun 11, 2025 · Today’s approval of taletrectinib (Ibtrozi; Nuvation Bio Inc) by the FDA for ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) comes on the heels of the …